L2 Bio looking for Principal Investigators for its Phase 2B adipose stem cell trial for Crohn’s Disease
The FDA has recently approved them for what appears to be an expanded adipose MSC trial, looking for GI experienced physicians.
The trial will examine IV administration of adipose-derived stem cells (ADSCs) from either the patient or a first-degree relative.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
“I have had over 100 submissions, approvals and clearances for my clients with the FDA over the past 20 plus years. This Crohn’s trial and the anticipated outcomes maybe one of the most exciting trials I have been involved with,” said Mukesh Kumar, PhD, Regulatory Advisor for L2 Bio.
L2 is looking for MDs and DOs specializing in gastrointestinal disorders such as Chron’s, Inflammatory Bowel Disease, etc.
Interested physicians are invited to submit their most recent Curriculum Vitae (CV) along with a brief paragraph detailing their relevant experience with Crohn’s Disease, IBD, or related conditions at www.L2Bio.com. Applicants will also be asked to complete five short screening questions.
Similar stories
Wolwo Bio Subsidiary Receives Chinese Trial Authorization for Umbilical Cord Mesenchymal Stem Cell Therapy for Sepsis
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy FacilityEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
